|
Shanghai Pharmaceuticals Holding Co., Ltd (2607.HK) DCF Valuation
CN | Healthcare | Medical - Distribution | HKSE
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Shanghai Pharmaceuticals Holding Co., Ltd (2607.HK) Bundle
Découvrez la valeur réelle de Shanghai Pharmaceuticals Holding Co., Ltd (2607HK) avec notre calculatrice avancée DCF! Ajustez les hypothèses critiques, explorez divers scénarios et examinez comment les changements affectent la valorisation de Shanghai Pharmaceuticals Holding Co., Ltd (2607HK) - le tout dans un modèle Excel facile à utiliser.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 199,228.8 | 204,934.8 | 230,473.1 | 247,726.8 | 277,962.4 | 302,296.0 | 328,759.9 | 357,540.4 | 388,840.6 | 422,880.8 |
| Revenue Growth, % | 0 | 2.86 | 12.46 | 7.49 | 12.21 | 8.75 | 8.75 | 8.75 | 8.75 | 8.75 |
| EBITDA | 9,980.1 | 11,153.6 | 11,263.7 | 13,287.0 | 11,645.1 | 15,049.5 | 16,367.0 | 17,799.8 | 19,358.1 | 21,052.8 |
| EBITDA, % | 5.01 | 5.44 | 4.89 | 5.36 | 4.19 | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 |
| Depreciation | 2,012.9 | 2,282.9 | 2,285.0 | 2,373.3 | 2,335.6 | 2,971.0 | 3,231.1 | 3,513.9 | 3,821.6 | 4,156.1 |
| Depreciation, % | 1.01 | 1.11 | 0.99146 | 0.95803 | 0.84025 | 0.98281 | 0.98281 | 0.98281 | 0.98281 | 0.98281 |
| EBIT | 7,967.1 | 8,870.7 | 8,978.6 | 10,913.7 | 9,309.6 | 12,078.6 | 13,135.9 | 14,285.9 | 15,536.5 | 16,896.6 |
| EBIT, % | 4 | 4.33 | 3.9 | 4.41 | 3.35 | 4 | 4 | 4 | 4 | 4 |
| Total Cash | 19,384.9 | 23,809.6 | 23,910.1 | 39,527.3 | 43,430.3 | 38,272.5 | 41,623.0 | 45,266.8 | 49,229.5 | 53,539.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 53,181.2 | 59,290.3 | 65,146.4 | 74,950.7 | 82,400.0 | 86,934.8 | 94,545.3 | 102,822.1 | 111,823.4 | 121,612.8 |
| Account Receivables, % | 26.69 | 28.93 | 28.27 | 30.26 | 29.64 | 28.76 | 28.76 | 28.76 | 28.76 | 28.76 |
| Inventories | 26,565.9 | 25,723.2 | 28,943.7 | 36,799.2 | 39,109.2 | 40,731.0 | 44,296.7 | 48,174.5 | 52,391.9 | 56,978.4 |
| Inventories, % | 13.33 | 12.55 | 12.56 | 14.85 | 14.07 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 |
| Accounts Payable | 26,697.4 | 24,451.5 | 44,845.8 | 55,065.5 | 58,340.6 | 53,208.2 | 57,866.2 | 62,932.0 | 68,441.2 | 74,432.8 |
| Accounts Payable, % | 13.4 | 11.93 | 19.46 | 22.23 | 20.99 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 |
| Capital Expenditure | -2,940.0 | -3,214.3 | -4,398.3 | -2,867.1 | -3,172.2 | -4,384.0 | -4,767.8 | -5,185.1 | -5,639.1 | -6,132.7 |
| Capital Expenditure, % | -1.48 | -1.57 | -1.91 | -1.16 | -1.14 | -1.45 | -1.45 | -1.45 | -1.45 | -1.45 |
| Tax Rate, % | 46.59 | 46.59 | 46.59 | 46.59 | 46.59 | 46.59 | 46.59 | 46.59 | 46.59 | 46.59 |
| EBITAT | 5,191.9 | 5,558.4 | 5,615.6 | 6,959.7 | 4,972.6 | 7,429.7 | 8,080.1 | 8,787.4 | 9,556.7 | 10,393.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -48,784.9 | -2,885.3 | 14,820.1 | -974.2 | -2,348.2 | -5,272.3 | 25.2 | 27.4 | 29.8 | 32.4 |
| WACC, % | 4.29 | 4.24 | 4.24 | 4.26 | 4.04 | 4.21 | 4.21 | 4.21 | 4.21 | 4.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4,960.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 33 | |||||||||
| Terminal Value | 1,492 | |||||||||
| Present Terminal Value | 1,214 | |||||||||
| Enterprise Value | -3,746 | |||||||||
| Net Debt | 13,219 | |||||||||
| Equity Value | -16,966 | |||||||||
| Diluted Shares Outstanding, MM | 3,701 | |||||||||
| Equity Value Per Share | -4.58 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-populated financial data for Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
- Comprehensive Data: Access to historical figures and future estimates (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Quickly observe how your inputs affect the valuation of Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
- Professional Resource: Designed for use by investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for easy navigation and understanding, accompanied by step-by-step guidance.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
- WACC Calculator: User-friendly Weighted Average Cost of Capital sheet with customizable input options.
- Adjustable Forecast Assumptions: Easily modify growth projections, capital expenditures, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
- Interactive Dashboard and Visual Charts: Graphical outputs present essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Shanghai Pharmaceuticals (2607HK), including historical and projected information.
- Step 3: Modify the key assumptions (yellow cells) according to your evaluation.
- Step 4: Observe the automatic updates that reflect Shanghai Pharmaceuticals' intrinsic value.
- Step 5: Utilize the results to inform your investment strategies or reporting needs.
Why Use Shanghai Pharmaceuticals Calculator?
- Precision: Leveraging genuine Shanghai Pharmaceuticals financial data for reliable results.
- Versatility: Engineered for users to easily experiment with and adjust input parameters.
- Efficiency: Eliminate the complications of constructing a DCF model from the ground up.
- Expert-Level Quality: Created with the meticulousness and usability standards suited for CFOs.
- Intuitive Design: Simple to navigate, even for those without extensive experience in financial modeling.
Who Can Benefit from This Product?
- Finance Students: Master valuation methodologies and apply them to real-world data.
- Academics: Integrate advanced financial models into your teaching or research initiatives.
- Investors: Validate your hypotheses and evaluate the valuation results of Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
- Analysts: Enhance your efficiency with a customizable, ready-to-use DCF model.
- Small Business Owners: Discover the analytical approaches used to assess large public companies like Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Shanghai Pharmaceuticals Holding Co., Ltd (2607HK), encompassing revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models that display intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Provides key profitability, leverage, and efficiency ratios specific to Shanghai Pharmaceuticals Holding Co., Ltd (2607HK).
- Dashboard and Charts: A visual summary of valuation outputs and assumptions for easy result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.